Posted by Michael Wonder on 14 Dec 2020
Advicenne receives positive CHMP opinion recommending approval of ADV7103 (sibnayal) for the treatment of distal renal tubular acidosis
11 December 2020 - Advicenne today announces the CHMP of the EMA adopted a positive opinion recommending approval of its lead product ADV7103 (Sibnayal) as therapy for distal renal tubular acidosis.
The European Commission will now review the CHMP recommendation and a final decision on the marketing authorisation of ADV7103 in the European Union is expected in the coming weeks/months.
